SER

Serina Therapeutics Inc

1.65

Nov 05 • 3:59 PM ET -0.04 (-2.37%)

1.65

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano AMEX

Peers: GANX ANVS ATHE CRVO VYGR IKT VANI PMN ADXN BIVI

| Held by: VTI VXF BUSM

Scroll to Statements

Index	-
Market Cap	41.91M
Enterprise Value	22.10M
Income	-23.82M
Sales	0.00M
Book/sh	0.74
Cash/sh	0.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Nov 29, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.24
P/C	1.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.65
Current Ratio	6.65
Debt/Eq	0.17
LT Debt/Eq	0.17
Option/Short	No / Yes

EPS (ttm)	-1.88
EPS next Y	-1.15
EPS next Q	-0.34
EPS this Y	17.35%
EPS next Y	26.95%
EPS next 5Y	18.02%
EPS past 3/5Y	41.84% 28.41%
Sales past 3/5Y	- 19.21%
EPS Y/Y TTM	67.71%
Sales Y/Y TTM	-
EPS Q/Q	15.42%
Sales Q/Q	-100.00%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-17.95% -

Insider Own	51.20%
Insider Trans	0.34%
Inst Own	10.02%
Inst Trans	-2.07%
ROA	-121.85%
ROE	-206.26%
ROIC	-96.52%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.62%
SMA50	-20.40%
SMA200	-20.19%
Trades

Shs Outstand	25.40M
Shs Float	12.40M
Short Float	0.35%
Short Ratio	0.63
Short Interest	0.04M
52W High	4.45 -62.90%
52W Low	1.22 35.25%
Volatility	21.86% 14.56%
ATR (14)	0.24
RSI (14)	39.26
Beta	1.27
Rel Volume	0.30
Avg Volume	69.91K
Volume	21,204

Perf Week	-12.70%
Perf Month	-17.91%
Perf Quarter	-31.25%
Perf Half Y	-8.84%
Perf YTD	-13.75%
Perf Year	-61.89%
Perf 3Y	-92.18%
Perf 5Y	-94.28%
Perf 10Y	-
Recom	1.00
Target Price	9.50
Prev Close	1.69
Price	1.65
Change %	-2.37%

Consensus

Strong Buy

Avg. Price Target

$9.50

Implied Upside

+475.8%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 01, 2026	Initiated	BBTIG Research	Buy	$8	+384.8%
Jul 14, 2025	Initiated	HH.C. Wainwright	Buy	$15	+809.1%

Sep-23-26 04:18PM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" (GlobeNewswire) -5.19%
Sep-10-26 04:05PM	Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -11.20%
Sep-09-26 07:45AM	Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 (GlobeNewswire)
Aug-13-26 04:15PM	Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-24-26 06:00AM	Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
06:00AM	Loading…
Jul-23-26 06:00AM	Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire)
Jul-22-26 04:30PM	Serina Therapeutics Appoints Farrell Simon to its Board of Directors (GlobeNewswire)
Jul-09-26 12:10PM	Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire) +10.00%
May-14-26 04:20PM	Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) +10.26%
Apr-07-26 06:00AM	Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit (GlobeNewswire)
Apr-02-26 04:13PM	Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan (GlobeNewswire)
Mar-25-26 04:20PM	Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +24.69% -13.86%
Mar-24-26 06:00AM	Serina Therapeutics to Present at the 38th Annual Roth Conference (GlobeNewswire) -22.86%
Mar-18-26 04:10PM	Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire) +93.75%
Feb-24-26 04:05PM	Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire) +6.37% +5.99%
06:00AM	Loading…
Feb-19-26 06:00AM	Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire)
Feb-03-26 06:00AM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event (GlobeNewswire)
Jan-29-26 12:09AM	What Sparked Serina Therapeutics (SER) 35% After-Hours Surge? (Benzinga) +30.15%
Jan-28-26 04:12PM	Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease (GlobeNewswire)
Jan-15-26 04:30PM	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity (GlobeNewswire) +15.24%
Dec-11-25 04:15PM	Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry (GlobeNewswire)
Dec-10-25 04:30PM	Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program (GlobeNewswire)
Nov-13-25 06:10AM	Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-03-25 06:05AM	Serina Therapeutics Provides Regulatory Update on SER-252 Program (GlobeNewswire) -6.40%
Oct-08-25 11:00AM	Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors (GlobeNewswire)
Oct-06-25 04:15PM	Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-09-25 03:20PM	Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-08-25 06:00AM	Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 04:52AM	These Stocks Are Moving the Most Today: Interactive Brokers, Talen Energy, Palantir, Nvidia, Serina Therapeutics, and More (Barrons.com)
Aug-25-25 04:15PM	Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway (GlobeNewswire)
04:30PM	Loading…
Aug-11-25 04:30PM	Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -7.44% +7.06%
Jul-29-25 06:44AM	Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) (GlobeNewswire)
Jul-28-25 06:00AM	Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) +5.83%
Jul-10-25 04:10PM	Serina Therapeutics Makes Grant to New Employee Under Inducement Plan (GlobeNewswire)
Jul-01-25 04:15PM	Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting (GlobeNewswire)
Jun-23-25 07:24PM	Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 (GlobeNewswire) +5.95%
Jun-17-25 08:30PM	UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
06:00AM	Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
Jun-09-25 04:05PM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" (GlobeNewswire)
May-22-25 04:50PM	Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors (GlobeNewswire) +8.87%
May-14-25 03:15PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
May-08-25 04:23PM	Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-29-25 06:00AM	Serina Therapeutics to Present at JonesResearch Virtual CNS Day (GlobeNewswire)
Apr-15-25 06:30AM	Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit (GlobeNewswire)
Apr-08-25 04:30PM	Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease (GlobeNewswire)
Apr-07-25 06:30AM	Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-24-25 04:30PM	Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting (GlobeNewswire)
Feb-12-25 04:15PM	Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors (GlobeNewswire)
Feb-03-25 04:30PM	Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -5.91%
Jan-15-25 04:05PM	Serina Therapeutics Announces Sale of UniverXome Subsidiary (GlobeNewswire)
Jan-14-25 05:25PM	Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors (GlobeNewswire)
Dec-16-24 06:00AM	Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 (GlobeNewswire) -7.98%
Dec-11-24 06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity and Toxicity Summit (GlobeNewswire) -9.16%
06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit (GlobeNewswire)
Dec-02-24 05:22PM	Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -9.52% +19.16%
Nov-12-24 05:00PM	Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-11-24 05:40PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +20.87%
Oct-02-24 08:30AM	Serina Therapeutics to Present at the 14th Annual Injectables Summit (GlobeNewswire)
Sep-04-24 06:42PM	Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 07:01PM	Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) (GuruFocus.com)
Aug-09-24 04:15PM	Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -5.17% -10.13%
Jul-29-24 08:30AM	Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit (GlobeNewswire)
Jul-18-24 05:00PM	Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation (GlobeNewswire) -18.15% +9.84%
May-15-24 07:30AM	Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinsons Disease (GlobeNewswire)
May-14-24 04:05PM	Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +11.13%
Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire) -9.64%
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90% +33.98%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brannan Stephen K.	Director	Jul 07 '26	Buy	2.03	1,000	2,030	1,000	Jul 09 12:05 PM
Venkatesan Jay	Director	May 22 '26	Buy	1.78	589	1,048	589	Jun 22 07:15 PM
WILSON KAREN J	Director	Jun 11 '26	Buy	1.75	5,100	8,900	5,100	Jun 15 10:31 AM
WILSON KAREN J	Director	Jun 12 '26	Buy	1.77	5,000	8,850	10,100	Jun 15 10:31 AM
WILSON KAREN J	Director	May 22 '26	Buy	1.93	10,000	19,300	20,000	May 26 04:26 PM
WILSON KAREN J	Director	May 21 '26	Buy	1.77	10,000	17,700	10,000	May 26 04:26 PM
Marshall Richard Peter	Director	May 19 '26	Buy	1.65	12,183	20,102	12,183	May 22 04:59 PM
Moreadith Randall	Chief Scientific Officer	Mar 23 '26	Option Exercise	0.06	6,500	390	6,500	Mar 24 07:24 PM
Moreadith Randall	Chief Scientific Officer	Mar 23 '26	Sale	2.86	6,500	18,568	0	Mar 24 07:24 PM
Moreadith Randall	Chief Scientific Officer	Mar 19 '26	Option Exercise	0.06	39,000	2,340	39,000	Mar 20 02:20 PM
Moreadith Randall	Chief Scientific Officer	Mar 19 '26	Sale	2.50	39,000	97,500	0	Mar 20 02:20 PM
Moreadith Randall	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.06	6,500	390	6,500	Feb 03 12:35 PM
Moreadith Randall	Chief Scientific Officer	Feb 02 '26	Sale	3.03	6,500	19,680	0	Feb 03 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 28 '26	Option Exercise	0.06	6,500	390	6,500	Jan 29 12:54 PM
Moreadith Randall	Chief Scientific Officer	Jan 28 '26	Sale	3.57	6,500	23,186	0	Jan 29 12:54 PM
Moreadith Randall	Chief Scientific Officer	Jan 22 '26	Option Exercise	0.06	2,500	150	2,500	Jan 23 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 22 '26	Sale	2.95	2,500	7,375	0	Jan 23 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 20 '26	Option Exercise	0.06	2,000	120	2,000	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 21 '26	Option Exercise	0.06	2,000	120	2,000	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 20 '26	Sale	3.07	2,000	6,140	0	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 21 '26	Sale	3.00	2,000	6,000	0	Jan 21 07:17 PM
Moreadith Randall	Officer	Jan 20 '26	Proposed Sale	3.07	91,000	279,370		Jan 20 04:20 PM
Moreadith Randall	Chief Scientific Officer	Jan 13 '26	Option Exercise	0.06	5,416	325	5,416	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 14 '26	Option Exercise	0.06	1,084	65	1,084	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 13 '26	Sale	2.50	5,416	13,540	0	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 14 '26	Sale	2.50	1,084	2,713	0	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 08 '26	Option Exercise	0.06	13,000	780	13,000	Jan 09 12:27 PM
Moreadith Randall	Chief Scientific Officer	Jan 08 '26	Sale	2.69	13,000	34,953	0	Jan 09 12:27 PM
Moreadith Randall	Chief Scientific Officer	Dec 23 '25	Option Exercise	0.06	4,100	246	4,100	Dec 29 11:40 AM
Moreadith Randall	Chief Scientific Officer	Dec 23 '25	Sale	2.60	4,100	10,660	0	Dec 29 11:40 AM
Moreadith Randall	Chief Scientific Officer	Dec 22 '25	Option Exercise	0.06	5,673	340	5,673	Dec 23 02:04 PM
Moreadith Randall	Chief Scientific Officer	Dec 22 '25	Sale	2.67	5,673	15,168	0	Dec 23 02:04 PM
Moreadith Randall	Chief Scientific Officer	Dec 16 '25	Option Exercise	0.06	3,227	194	3,227	Dec 17 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 16 '25	Sale	2.96	3,227	9,562	0	Dec 17 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 12 '25	Option Exercise	0.06	1,700	102	1,700	Dec 16 06:59 PM
Moreadith Randall	Chief Scientific Officer	Dec 12 '25	Sale	3.26	1,700	5,541	0	Dec 16 06:59 PM
Moreadith Randall	Chief Scientific Officer	Dec 11 '25	Option Exercise	0.06	3,555	213	3,555	Dec 12 12:48 PM
Moreadith Randall	Chief Scientific Officer	Dec 11 '25	Sale	3.24	3,555	11,520	0	Dec 12 12:48 PM
Moreadith Randall	Chief Scientific Officer	Dec 09 '25	Option Exercise	0.06	600	36	600	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 10 '25	Sale	3.35	645	2,161	0	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 09 '25	Sale	3.31	600	1,988	0	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 03 '25	Option Exercise	0.06	5,000	300	5,000	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 02 '25	Option Exercise	0.06	1,500	90	1,500	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 03 '25	Sale	3.52	5,000	17,623	0	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 02 '25	Sale	3.91	1,500	5,858	0	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Nov 25 '25	Option Exercise	0.06	5,965	358	11,930	Nov 26 05:21 PM
Moreadith Randall	Chief Scientific Officer	Nov 25 '25	Sale	3.90	5,965	23,264	5,965	Nov 26 05:21 PM
Moreadith Randall	Chief Scientific Officer	Nov 24 '25	Option Exercise	0.06	535	32	535	Nov 25 09:20 PM
Moreadith Randall	Chief Scientific Officer	Nov 24 '25	Sale	3.94	535	2,105	0	Nov 25 09:20 PM
Moreadith Randall	Chief Scientific Officer	Nov 18 '25	Option Exercise	0.06	6,500	390	6,500	Nov 19 01:47 PM
Moreadith Randall	Chief Scientific Officer	Nov 18 '25	Sale	3.75	6,500	24,402	0	Nov 19 01:47 PM
Moreadith Randall	Chief Scientific Officer	Nov 10 '25	Option Exercise	0.06	6,500	390	6,500	Nov 12 12:38 PM
Moreadith Randall	Chief Scientific Officer	Nov 10 '25	Sale	4.10	6,500	26,650	0	Nov 12 12:38 PM

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley in 2006 and is headquartered in Huntsville, AL.

Executive Co-Chairman of the BoardDr. Balkrishan Gill Ph.D.

CEO & DirectorMr. Steven A. Ledger

Co-FounderDr. J. Milton Harris Ph.D.

Chief Technical Operations OfficerDr. Srini Tenjarla Ph.D.

Ph.D.Dr. Randall W. Moreadith M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SER

Serina Therapeutics Inc

Upgrade your Finviz experience